stock setter

$ALNY -Cowen lowers Alnylam Pharmaceuticals target to $354 from $482 Buy -UBS lowers target to $329 from $354 Buy -Goldman lowers target to $320 from $536 Buy -Raymond James lowers target to $315 from $420 Downgrades from Outperform from Strong Buy -BMO lowers target to $290 from $318 Outperform -Bank of America lowers target to $287 from $336 Buy -RBC lowers target to $280 from $345 Outperform -Morgan Stanley lowers target to $240 from $300 = Weight -Wells Fargo lowers target to $220 from $253 = Weight -Bernstein lowers target to $199 from $376 Downgrades to Market Perform from Outperform

$ALGM -Mizuho lowers Allegro target to $48 from $56 Outperform -Barclays lowers target to $45 from $48 = Weight - $ALHC -Piper Sandler lowers Alignment Healthcare target to $15 from $30 Overweight -Barclays lowers target to $9 from $10 = Weight -KeyBanc downgrades to Sector weight from Overweight

$AKAM -Guggenheim reiterates Akamai coverage at Buy amid Anthropic deal The firm believes full-year 2026 total revenue guidance is attainable -Maintains $225 target investing.com/news/analyst-r…

$AJG -RBC raises Arthur J. Gallagher target to $315 from $290 Outperform -Mizuho raises target to $302 from $271 Outperform -Goldman maintains $296 target Buy -Keefe Bruyette raises target to $275 from $242 Market Perform -Truist raises target to $275 from $265 Hold

Stock market rocked as investors dump tech shares, Nasdaq drops 3%: Live updates cnb.cx/4iOcRny

$ABOS -Stifel downgrades Acumen Pharmaceuticals to Hold from Buy after trial fails -Stifel expressed skepticism about Acumen's remaining candidate, noting it also targets oligomers and that greater brain penetration would be unlikely to yield a different outcome based on the available top-line data -Lowers target to $1 from $10 ca.investing.com/news/stock-…

$ABCL -Jefferies initiates AbCellera coverage with a Buy rating -The firm highlighted the company’s antibody discovery platform and its clinical pipeline, led by ABCL635, a monthly subcutaneous NK3R antibody for vasomotor symptoms. -Sets $21 target investing.com/news/analyst-r…

$BJDX Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split The reverse stock split will be effective November 3, 2026, at 12:01 a.m. Eastern Time stocktitan.net/news/BJDX/blu…

$CHOW ChowChow Cloud Announces Closing of Previously Announced Private Placement - The company issued 86,207 restricted Class A Ordinary Shares at US$5.80 per share. It received the remaining purchase price on October 26, completing payment of the full US$500,000. stocktitan.net/news/CHOW/cho…

$PMN ProMIS Neuroscience Down ~50% After Acumen's Alzheimer's Trial Failure -Since both ProMIS and Acumen Pharmaceuticals $ABOS pursue a similar oligomer-selective anti-amyloid approach (as opposed to broader plaque-clearing antibodies), ABOS’s Phase 2 failure is pressuring names like PMN -Market commentary has noted differences (e.g., in selectivity, half-life, IgG subclass, and dosing), and PMN is at an earlier stage with its own interim safety/biomarker signals, but the peer setback is still weighing heavily on the stock in a volatile micro-cap biotech. (Source: Grok)

$OSPN OneSpan Q3 2026: subscription surge drives guidance raise - The company reported revenue of $63.9 million, up 12% year-over-year, while subscription revenue surged 16% to reach $51.5 million, representing a record 81% of total revenue. investing.com/news/company-n…

$CDNA CareDx earnings beat by $0.44, revenue topped estimates - Revenue for the quarter came in at $139M versus the consensus estimate of $121.95M investing.com/news/earnings/…

$GDYN Grid Dynamics Q3 2026 slides: record margins fuel stock surge - he San Ramon, California-based digital engineering firm reported revenue of $114.3 million and non-GAAP EBITDA of $22.9 million, representing a 20% margin that exceeded management’s expansion targets one quarter ahead of schedule investing.com/news/company-n…

$IRMD Iradimed Reports Third Quarter 2026 Results - Iradimed reported revenue of $24.2 million, up 14% from the same period in 2025. - Revenue rose 18% from the second quarter. - Net income increased 17% year over year to $6.5 million, with GAAP diluted earnings per share rising to $0.51 from $0.43. -mGross margin fell to 76% from 78% a year earlier, although the company reported sequential improvement as production of its 3870 infusion pump increased. -- Iradimed expects fourth-quarter revenue of $25.0 million to $26.5 million stocktitan.net/news/IRMD/ira…

$OABI OmniAb Q3 2026 Revenue Beat and Raised Guidance Offset by Sell-the-News Pressure - Management raised 2026 revenue guidance to $35 million to $39 million from $32 million to $36 million, and lifted its year-end cash outlook to $53 million to $57 million from $49 million to $53 million chartmill.com/news/OABI/Char…

$SXT Sensient Technologies reports third-quarter 2026 revenue of $455.8 million, up 10.6% from $412.1 million a year earlier - Operating income increased 25.5% to $72.4 million, while diluted EPS rose 29.9% to $1.13. - Management expressed confidence in its 2026 outlook, citing business momentum, customer demand and investments supporting future growth. grafa.com/news/united-states…

$AN AutoNation Shares Rise as Revenue Beats Forecasts Despite Earnings Miss - Adjusted earnings per share of $5.11 were slightly below Wall Street's consensus estimate of $5.17, but revenue reached $7.0 billion, exceeding expectations of $6.93 billion finance.yahoo.com/markets/st…

$LYB LyondellBasell Q3 profit comes in at $758 million as revenue rises - LyondellBasell reported third-quarter 2026 net income of $758 million, reversing a $905 million loss in the same quarter last year. grafa.com/news/united-states…

$NVT nVent Electric earnings beat by $0.13, revenue tops estimates - Revenue for the quarter came in at $1.5B versus the consensus estimate of $1.43B investing.com/news/earnings/…